186 related articles for article (PubMed ID: 35405351)
1. Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series.
Soman R; Chakraborty S; Joe G
Int J Infect Dis; 2022 Jul; 120():177-178. PubMed ID: 35405351
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring of posaconazole delayed release tablet while managing COVID-19-associated mucormycosis in a real-life setting.
Patel A; Patel K; Patel K; Shah K; Chakrabarti A
Mycoses; 2022 Mar; 65(3):312-316. PubMed ID: 34953080
[TBL] [Abstract][Full Text] [Related]
3. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.
Bagshaw E; Kuessner D; Posthumus J; Escrig C; Blackney M; Heimann SM; Cornely OA
Future Microbiol; 2017 May; 12():515-525. PubMed ID: 28191796
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.
Gebremariam T; Alkhazraji S; Baldin C; Kovanda L; Wiederhold NP; Ibrahim AS
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264840
[TBL] [Abstract][Full Text] [Related]
5. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.
Ervens J; Ghannoum M; Graf B; Schwartz S
Infection; 2014 Apr; 42(2):429-32. PubMed ID: 24217961
[TBL] [Abstract][Full Text] [Related]
6. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
7. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.
Cornu M; Bruno B; Loridant S; Navarin P; François N; Lanternier F; Amzallag-Bellenger E; Dubos F; Mazingue F; Sendid B
BMC Pharmacol Toxicol; 2018 Dec; 19(1):81. PubMed ID: 30522521
[TBL] [Abstract][Full Text] [Related]
8. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Miceli MH; Kauffman CA
Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
[TBL] [Abstract][Full Text] [Related]
9. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
[TBL] [Abstract][Full Text] [Related]
10. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
Patel A; Agarwal R; Rudramurthy SM; Shevkani M; Xess I; Sharma R; Savio J; Sethuraman N; Madan S; Shastri P; Thangaraju D; Marak R; Tadepalli K; Savaj P; Sunavala A; Gupta N; Singhal T; Muthu V; Chakrabarti A;
Emerg Infect Dis; 2021 Sep; 27(9):2349-2359. PubMed ID: 34087089
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis.
Gebremariam T; Gu Y; Singh S; Kitt TM; Ibrahim AS
J Antimicrob Chemother; 2021 Sep; 76(10):2636-2639. PubMed ID: 34263306
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole treatment of a patient with disseminated mucormycosis.
Peixoto D; Gagne LS; Hammond SP; Gilmore ET; Joyce AC; Soiffer RJ; Marty FM
J Clin Microbiol; 2014 Mar; 52(3):1016-9. PubMed ID: 24403304
[TBL] [Abstract][Full Text] [Related]
13. Drug repurposing of triazoles against mucormycosis using molecular docking: A short communication.
Mhatre S; Patravale V
Comput Biol Med; 2021 Sep; 136():104722. PubMed ID: 34358995
[TBL] [Abstract][Full Text] [Related]
14. Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK.
Bagshaw E; Enoch DA; Blackney M; Posthumus J; Kuessner D
Future Microbiol; 2018 Sep; 13(11):1283-1293. PubMed ID: 29911889
[TBL] [Abstract][Full Text] [Related]
15. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.
Gebremariam T; Wiederhold NP; Alqarihi A; Uppuluri P; Azie N; Edwards JE; Ibrahim AS
J Antimicrob Chemother; 2017 Feb; 72(2):462-466. PubMed ID: 27798213
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir.
Terrier J; Zanella MC; Masouridi-Levrat S; Kronig I; Chalandon Y; Vernaz N; Van Delden C; Papanicolaou G; Neofytos D
Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782007
[TBL] [Abstract][Full Text] [Related]
17. Part 2: mucormycosis: focus on therapy.
Lynch JP; Zhanel GG
Expert Rev Anti Infect Ther; 2023; 21(7):737-748. PubMed ID: 37300820
[TBL] [Abstract][Full Text] [Related]
18. Utility of itraconazole and terbinafine in mucormycosis: a proof-of-concept analysis.
Gupta P; Malhotra HS; Saxena P; Singh R; Shukla D; Hasan MS; Verma V; Banerjee G; Puri B; Dandu H
J Investig Med; 2022 Apr; 70(4):914-918. PubMed ID: 35078866
[TBL] [Abstract][Full Text] [Related]
19. Isavuconazole As Successful Salvage Therapy for Mucormycosis in Pediatric Patients.
Ashkenazi-Hoffnung L; Bilavsky E; Levy I; Grisaru G; Sadot E; Ben-Ami R; Novikov A; Fischer S; Nahum E; Scheuerman O
Pediatr Infect Dis J; 2020 Aug; 39(8):718-724. PubMed ID: 32251256
[TBL] [Abstract][Full Text] [Related]
20. Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents.
Hussain MK; Ahmed S; Khan A; Siddiqui AJ; Khatoon S; Jahan S
Eur J Med Chem; 2023 Jan; 246():115010. PubMed ID: 36566630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
